Biopharma nurtures the next generation of immuno-oncology targets

On Sept. 1, Gilead struck a development deal for an immuno-oncology asset—the value of which spoke volumes about the industry’s enthusiasm for emerging immune targets for treating cancer.

Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *